0 items
Your cart is empty.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
$82.00
This product is available by prescription only
This product does not require a prescription
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
The product is delivered in powdered (lyophilized) form and must be properly reconstituted prior to research use.
The 10mg vial provides high peptide availability for extended multi-phase research programs, reducing vial requirements and simplifying laboratory inventory management across long-duration protocols. Lyophilized pharmaceutical-grade format ensures stability for multi-month experimental designs, supporting consistent peptide exposure and reproducible molecular endpoint data throughout the observation period. The concentration is particularly suited to professional research facilities managing multiple concurrent GHRH pathway study arms simultaneously.
Sermorelin is a synthetic 29-amino acid analog corresponding to the biologically active N-terminal fragment of endogenous GHRH. It binds pituitary GHRH receptors and initiates Gs-protein-coupled cAMP signaling cascades that regulate somatotroph cell GH secretion pathway activity. Unlike exogenous GH administration, Sermorelin operates through endogenous pituitary receptor mechanisms, preserving natural pulsatile secretion dynamics and feedback regulatory pathway activity. This physiological activation profile makes it a relevant model compound for studying intact somatotropic axis signaling behavior over extended experimental observation windows without receptor desensitization-associated confounds.
Novera supplies Sermorelin 10mg sourced from USA GMP-certified manufacturing facilities, independently verified to approximately 99% purity by third-party COA documentation. Each vial confirms the complete 29-amino acid sequence identity, purity grade, and batch-specific quality control data — providing professional laboratories with consistent, pharmaceutical-grade GHRH analog material for advanced somatotropic axis signaling research.
Sermorelin 10mg is suited for professional research institutions and laboratories conducting extended-duration GHRH analog receptor pharmacology investigations. Research teams running 24–48 week somatotropic axis signaling characterization programs, long-term pituitary receptor interaction studies, or multi-phase IGF-1 pathway marker quantification protocols benefit from this high-concentration format, which reduces vial turnover and simplifies procurement across extended observation periods. Laboratories examining the mechanistic basis of GHRH receptor activation, pulsatile GH secretion pathway dynamics, or feedback regulation marker expression in preclinical model systems will find this concentration suited to sustained experimental program designs. Novera supplies Sermorelin 10mg sourced from USA GMP-certified manufacturing facilities, with each vial COA-verified for purity and sequence identity to approximately 99%.
Sermorelin supports in-vitro investigation of GHRH receptor binding kinetics, receptor occupancy dynamics, and downstream cAMP second messenger pathway activity in pituitary somatotroph cell line and primary culture models. Researchers characterizing GHRH analog binding affinity profiles, receptor subtype selectivity parameters, and signal transduction cascade dynamics use Sermorelin as a primary reference agonist for comparative GHRH receptor pharmacology study designs.
Laboratories studying the hypothalamic-pituitary somatotropic axis use Sermorelin to quantify downstream molecular marker activity including GH secretion assay endpoints, IGF-1 pathway signaling marker expression, and somatostatin feedback interaction dynamics in controlled preclinical systems. Extended multi-timepoint study designs allow systematic observation of signaling cascade progression, pulsatile secretion pattern characterization, and regulatory feedback mechanism activity across long-duration experimental observation windows.
Sermorelin’s physiological receptor activation mechanism makes it suited to extended laboratory studies examining GHRH receptor activity maintenance, feedback loop regulatory marker dynamics, and somatotroph cell responsiveness progression over 24–48 week observation periods. Research teams investigating whether sustained GHRH analog exposure maintains receptor sensitivity and pulsatile pathway activity without desensitization-associated endpoint changes use Sermorelin’s endogenous-pathway mechanism as a key study design advantage.
Sermorelin’s 29-amino acid structure — representing the minimum biologically active GHRH fragment — makes it a useful reference compound for studies comparing GHRH analog structural length, modification profiles, and their consequences for receptor binding duration, half-life kinetics, and downstream somatotropic axis signaling marker activity. Researchers examining structure-activity relationships in GHRH peptide pharmacology use Sermorelin alongside longer or structurally modified analogs such as Tesamorelin for comparative mechanistic characterization.
Reconstitute lyophilized Sermorelin 10mg with sterile bacteriostatic water using standard sterile laboratory technique under controlled conditions. Reconstitution volume should be determined based on the target experimental working concentration specified by the study design. Use calibrated laboratory equipment throughout all preparation steps and document reconstitution in accordance with institutional research record-keeping standards.
Store lyophilized peptide at 2–8°C in a controlled, dark laboratory environment prior to reconstitution. Following reconstitution, maintain strict refrigeration at 2–8°C to preserve GHRH analog peptide integrity. This product does not require cold-chain shipping, but immediate refrigeration upon receipt is recommended to ensure optimal stability throughout the protocol period. Each vial supplied by Novera includes COA documentation and handling guidance.
Professional research programs typically employ 24–48 week protocols for comprehensive GHRH receptor and somatotropic axis characterization. Extended studies systematically monitor IGF-1 pathway signaling markers, GH secretion assay endpoints, and downstream metabolic pathway marker expression at defined experimental intervals. The 10mg concentration supports efficient multi-year professional research designs, minimizing procurement interruption across extended observation phases. Document findings in accordance with institutional data management standards for publication-quality reproducibility.
Novera Research delivers high-quality research peptides developed under strict manufacturing and quality-control standards. Each product is carefully synthesized, tested, and handled to ensure consistency, reliability, and transparency for advanced research applications.
High-purity, research-grade peptide synthesis
Analytical testing to verify quality and composition
Consistent batch-to-batch performance
Batch identification on every vial for traceability
Stored and shipped under controlled conditions
Research-grade synthetic peptide formulated in mid-range 10mg quantity for cellular migration studies and peptide actin-binding research in controlled laboratory environments.
Explore GHK-CU BPC-157 Tb-500 KPV Klow Blend, Novera's most advanced peptide blend. This superior four-peptide formula delivers unmatched benefits for skin and tissue repair, inflammatory balance, and rapid recovery.
Research-grade synthetic peptide inhibitor designed for experimental peptide-protein interaction research in controlled laboratory settings.
A synthetic GHRH analog studied for receptor binding kinetics, molecular interaction modeling, and pulsatile signaling pathway investigation in preclinical settings.
